Baloxavir Marboxil

玛巴洛沙韦

Report date: 2026/05/02 20:00:18
NMEFirst In ClassQIDP

Base Information

Drug NameBaloxavir Marboxil
Drug Alias Name巴洛沙韦玛波西酯巴洛沙韦酯Xofluza速福达RG-6152 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolymerase acidic protein inhibitors
TargetsPolymerase acidic protein
Therapy Area/IndicationsInfluenza A virus infectionsInfluenza, HumanRespiratory Tract Infections +[4] 
Global Approved IndicationsInfluenza A virus infectionsInfluenza, HumanInfluenza B virus infection
Approved Indications in ChinaInfluenza A virus infectionsInfluenza, HumanInfluenza B virus infection
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)University of ZurichRoche Pharma (Schweiz) Ag +[10] 
Inactive CompaniesShionogi Pharma Co Ltd
Active IndicationsInfluenza A virus infectionsInfluenza, HumanRespiratory Tract Infections +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AX25
Related LinksWikipediaDrugBank